艾伏尼布治疗胆管癌优先评审，治疗效果怎么样

Cholangiocarcinoma is a very aggressive tumor, but the drug has improved the overall survival (OS) of patients with cholangiocarcinoma. Many patients do not know much about the drug ivosidenib. They don’t know how effective it is, whether it can treat cholangiocarcinoma, whether it is on the market, and whether it can be purchased. Today we will learn more about the priority review of ivosidenib for the treatment of cholangiocarcinoma. How is the treatment effect?

Ivonib has been accepted by the U.S. Food and Drug Administration (FDA) for review indications for the treatment of previously treated cholangiocarcinoma patients carrying isocitrate dehydrogenase-1 (IDH1) mutations. Moreover, the review time of Ivonib has been shortened from 10 months to 6 months, and it has been included in priority review. So, what is the therapeutic effect of Ivonib?

Data from a phase 3 clinical trial called ClarIDHy showed that compared to placebo, ivonib reduced patients' risk of disease progression or death by 63%, which means that ivonib met the primary endpoint of progression-free survival (PFS). Ivonib is an oral IDH1-targeted inhibitor originally developed by Agios Pharmaceuticals. In 2018, Agios reached an exclusive agreement with CStone Pharmaceuticals to develop and commercialize ivosidenib in Greater China. Moreover, ivosidenib was previously marketed for the treatment of adult patients with IDH1-mutated relapsed/refractory acute myeloid leukemia (R/R AML).

No matter how good the oncology drug is, it will have side effects, and ivosidenib is no exception. The most common adverse reactions (≥20%) of ivosidenib are fatigue, leukocytosis, nausea, electrocardiogram QT prolongation, rash, arthritis, diarrhea, edema, mucositis, fever, cough, dyspnea and constipation.

Although Ivonib is very effective, it is still urgently needed in China and has not yet been launched on the market, let alone reimbursed by medical insurance. If patients need Ivonib drugs, they can obtain the drugs through overseas medical service agencies (such as Medical Companion Travel). It is cost-effective, reduces the cost of patients going abroad to purchase drugs, and guarantees the authenticity of the drugs.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: